Navigation Links
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
Date:2/27/2009

l storage disorders. Under the agreement, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

About Pompe Disease

Pompe disease affects an estimated 5,000-10,000 individuals world-wide and is clinically heterogeneous in the age of onset, the extent of organ involvement, and the rate of progression. The early onset form of the disease is the most severe, progresses most rapidly, and is characterized by musculoskeletal, pulmonary, gastrointestinal, and cardiac symptoms that usually lead to death from cardio-respiratory failure between 1 and 2 years of age. The late onset form of the disease begins between childhood and adulthood and has a slower rate of progression that is characterized by musculoskeletal and pulmonary symptoms that usually lead to progressive muscle weakness and respiratory insufficiency. A high majority of patients have the late onset form of the disease. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in AT2220 in the United States.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Forward-Looking Statements


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... WASHINGTON , July 31, 2014  Today,s ... relievers serves as an important reminder for consumers ... reinforces the importance of initiatives such as the ... Dose consumer education campaign. Formed in ... health, healthcare provider and consumer organizations dedicated to ...
(Date:7/31/2014)... 2014 De Pfizer Clinical Research Unit (PCRU) ... vrijwilligers van Japanse komaf voor medewerking aan klinisch onderzoek. ... is één van twee onderzoekseenheden van Pfizer , ... verbeteren door de ontdekking en ontwikkeling van nieuwe medicijnen. ... naar mannen en vrouwen van Japanse komaf – leeftijd ...
(Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
Breaking Medicine Technology:U.S. Health Coalition Calls for Continued Education on Acetaminophen, America's Most Common Drug Ingredient 2Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2
... and Chromium Histidinate Down-regulate Gene in Brain that ... and Efficacy of Nutrition 21,s Chromax Chromium PicolinatePURCHASE, ... NXXI ), the developer and marketer ... Diabetes Essentials brands, recently presented results of a ...
... First Pivotal Phase 3 Avanafil Study REVIVE (TA-301) is ... (Nasdaq: VVUS ), a biopharmaceutical company developing ... diabetes and sexual health, today announced that it has ... investigational drug, avanafil, in males with erectile dysfunction (ED). ...
Cached Medicine Technology:New Research Shows Nutrition 21's Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings 2New Research Shows Nutrition 21's Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings 3New Research Shows Nutrition 21's Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings 4VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction 2VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction 3
(Date:7/31/2014)... India (PRWEB) July 31, 2014 Reputation ... launched a new service named ‘Remove Bad Reviews’. The ... bad reviews are published on various review sites. ... the world of internet marketing, the sites that allow ... competitors in order to tailor the service. , ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 FITNESS SF, ... Francisco, announced that they will upgrade all locations to ... MyClub, and MoSo Pay. Motionsoft is a leading provider ... that automate member management and payments services for health ... relationship management suite, which FITNESS SF bundled with the ...
(Date:7/31/2014)... 31, 2014 Web Programming Services, a ... certified internet marketing firm, has recently launched a new ... this service affordable for everyone, the company has announced ... , Web Programming Services has tailored the service ... brochure designing and likely expectations of the clients from ...
(Date:7/31/2014)... time after surgery may be reduced for patients taking ... new study. The study,s Irish researchers suspect that ... the amount of time surgical patients, wounds need to ... people who tend to have healing complications. "Statins ... in the world. While they are typically used to ...
(Date:7/31/2014)... Ethane Web Technologies, an ISO ... new service named ‘Java Development’. The service cost ... designed the service after doing a serious study ... service being provided by other web development companies. ... promise outstanding Java Development service. ...
Breaking Medicine News(10 mins):Health News:Reputation Management India Launches a New Service Called ‘Remove Bad Reviews’ 2Health News:FITNESS SF Upgrades Motionsoft Software to Include Entire Product Lineup: MoSo + MoSo Pay + MyClub 2Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2
... Julian ... searchbodydetox.com, a new informational Web site devoted to all aspects of whole body cleansing and ... Potomac, MD (Vocus) ... movement, is now a featured expert on searchbodydetox.com , a new informational Web site ...
... at Georgia State University have found that diets high in ... foods and beverages impaired the spatial memory of adult ... of Marise Parent, associate professor at Georgia State,s Neuroscience Institute ... a diet where fructose represented 60 percent of calories ingested ...
... , , MILWAUKEE, July 16 ... the nation in two different specialties, according to US News and ... same publication, St. Luke,s and Aurora Sinai Medical Center were recognized by ... , , (Logo: ...
... SWITZERLAND, July 16 /PRNewswire-FirstCall/ - BELLUS Health (International) Limited, ... Health, TSX: BLU), today announced that the Italian Ministry ... for VIVIMIND(TM) (homotaurine) as a food supplement. A certificate ... of the product in that country. This certificate opens ...
... , PHILADELPHIA, July 16 On Wednesday, ... its second quarter financial results for the three months ended June ... released to the London Stock Exchange at approximately 7:00 AM ... the announcement, Andrew Witty, Chief Executive Officer, Julian Heslop, Chief Financial ...
... ... just launched on Monday. , ... (Vocus) July 16, 2009 -- The National Practice Transition Network (NPTN), created ... practice sales and appraisals, is the first membership-based, commission-free organization to offer such a menu ...
Cached Medicine News:Health News:Dr. Julian Whitaker Featured on Searchbodydetox.com 2Health News:Researchers find that eating high levels of fructose impairs memory in rats 2Health News:Aurora's Milwaukee Hospitals Recognized in US News and World Report 2Health News:VIVIMIND(TM) granted certificate of free sale as food supplement in Italy - Premarket notification filed in the U.S. 2Health News:VIVIMIND(TM) granted certificate of free sale as food supplement in Italy - Premarket notification filed in the U.S. 3Health News:National Practice Transition Network Launches as the Country's First Membership-Based, Commission-Free Dental Practice Transition Company 2
A One Piece Support Garment - any length or size...
Body Suit w/Bra torso, Front Closure...
Gynecomastia Vest...
Ideal for breast compression and contouring breast cups....
Medicine Products: